Literature DB >> 22890318

Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity.

C Zhen1, L Chen, Q Zhao, B Liang, Y-X Gu, Z-F Bai, K Wang, X Xu, Q-y Han, D-f Fang, S-x Wang, T Zhou, Q Xia, W-L Gong, N Wang, H-Y Li, B-F Jin, J-h Man.   

Abstract

Tumor metastasis is responsible for most cancer patients' deaths. Understanding the mechanism of metastasis is crucial for improving the cure rate for cancer. Here, we report that Gankyrin, a chaperone of ubiquitin-proteasome, has an essential role in breast cancer metastasis. We find that Gankyrin is highly overexpressed in human breast cancers and the expression correlates strongly with lymph node metastasis. Knocking down Gankyrin expression in highly metastatic human breast cancer cells significantly decreases cancer cell migration and invasion. Furthermore, we demonstrate that depletion of Gankyrin inhibits intrinsic Rac1 activity and induces large focal adhesions. Overexpression of Gankyrin accelerates focal adhesion turnover and increases cell migration. Notably, reduction of Gankyrin expression in mouse mammary tumor cell significantly decreases tumor metastasis to lung in animal models. Therefore, our findings suggest that Gankyrin is crucial for breast cancer metastasis and highlight the potential of Gankyrin as a therapeutic target for tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890318     DOI: 10.1038/onc.2012.356

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

Review 1.  Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

Authors:  Christine S Muli; Wenzhi Tian; Darci J Trader
Journal:  Chembiochem       Date:  2019-05-24       Impact factor: 3.164

Review 2.  Gankyrin as a potential target for tumor therapy: evidence and perspectives.

Authors:  Haixai Li; Junyan Zhang; Cheng Zhen; Baojun Yang; Limin Feng
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

3.  TGF-β1 signaling pathway serves a role in HepG2 cell regulation by affecting the protein expression of PCNA, gankyrin, p115, XIAP and survivin.

Authors:  Xin-Hong Wang; Zhi-Guo Chen; Rui-Ling Xu; Cheng-Qian Lv; Jing Liu; Bing Du
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

4.  Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.

Authors:  Alex M Chapman; Brian R McNaughton
Journal:  ACS Chem Biol       Date:  2015-05-22       Impact factor: 5.100

5.  Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.

Authors:  Dipti Kanabar; Mimansa Goyal; Emma I Kane; Tejashri Chavan; Abbas Kabir; Xuechun Wang; Snehal Shukla; Joseph Almasri; Sona Goswami; Gizem Osman; Marino Kokolis; Donald E Spratt; Vivek Gupta; Aaron Muth
Journal:  J Med Chem       Date:  2022-06-27       Impact factor: 8.039

6.  Upregulation of PSMD10 caused by the JMJD2A histone demethylase.

Authors:  Tae-Dong Kim; Sangphil Oh; Stan A Lightfoot; Sook Shin; Jonathan D Wren; Ralf Janknecht
Journal:  Int J Clin Exp Med       Date:  2016-06-30

Review 7.  Gankyrin regulates cell signaling network.

Authors:  Xinxin Wang; Bin Jiang; Yanjie Zhang
Journal:  Tumour Biol       Date:  2016-01-27

8.  p28GANK overexpression is associated with chemotherapy resistance and poor prognosis in ovarian cancer.

Authors:  Ge Yu; Na Li; Wei Wang; Ming Niu; Xiaoling Feng
Journal:  Oncol Lett       Date:  2019-11-13       Impact factor: 2.967

9.  Involvement of PSMD10, CDK4, and Tumor Suppressors in Development of Intrahepatic Cholangiocarcinoma of Syrian Golden Hamsters Induced by Clonorchis sinensis and N-Nitrosodimethylamine.

Authors:  Md Hafiz Uddin; Min-Ho Choi; Woo Ho Kim; Ja-June Jang; Sung-Tae Hong
Journal:  PLoS Negl Trop Dis       Date:  2015-08-27

10.  Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway.

Authors:  X Zhao; J Fu; A Xu; L Yu; J Zhu; R Dai; B Su; T Luo; N Li; W Qin; B Wang; J Jiang; S Li; Y Chen; H Wang
Journal:  Cell Death Dis       Date:  2015-05-07       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.